Drostanolone

Form	Chemical record
Parent	C20H32O2; CAS 58-19-5
Propionate	C23H36O3; CAS 521-12-0
Enanthate	C27H44O3; CAS 13425-31-5

Human evidence

Most direct clinical reports are historical cancer or breast-condition studies. Other records concern oral treatment in kidney disease, hormone measurements, urinary detection and mixed-steroid exposures. Their routes and populations differ.^{1582,1583,1584}

Historical breast-cancer studies

6 of 20

Di Pietro and Salvadori report six objective improvements among 20 women with advanced breast cancer.¹⁵⁸⁵

A controlled comparison

A 91-patient study compared drostanolone, nandrolone and testololactone. It found no efficacy difference among groups. Cyclophosphamide was added during the later treatment interval.¹⁵⁸²

The dose comparison

A historical propionate comparison reported regression in 22% at the lower exposure and 16% at the higher exposure, with P=.325 and no reported survival difference. Arm sizes and duration are absent from the publisher abstract.¹⁵⁸⁶

Populations and comparators

The Masteril abstract reports differing response directions across comparisons with oophorectomy, nandrolone and estrogen in different menopausal groups. It omits group denominators and allocation details.¹⁵⁸⁷

Japanese and Mexican clinical records

Japan: a 40-patient comparison

A nonrandomized historical series compared propionate with testosterone propionate in 20 patients per group. Objective improvement was reported in 7/20 versus 5/20. Many patients also underwent endocrine surgery, so the comparison includes combined treatment.¹⁵⁸⁸

Japan: benign breast conditions

The dose study evaluated 38 women with mastopathy. A later comparator paper reused its drostanolone controls. Those two publications share treatment groups and cannot be summed as independent cohorts.^1589,1590

Mexico: primary indexed passages

A 1960 UNAM report describes 23 treated patients, 20 evaluable and three lost to follow-up. Its indexed table lists11 improved and nine failures. The direct article download was blocked; only primary-publisher indexed passages were read.¹⁵⁹¹

Urine studies

5.31 hours

A three-volunteer Korean study reports an unchanged-drug urinary-excretion half-life of 5.31 hours. Methods identify an oral propionate exposure.¹⁵⁹²

The measured endpoint

The article recovered about 3% of the administered amount as unchanged drug through 95 hours. Methods and Table 1 use different collection-time labels. The study did not measure plasma concentrations or an intramuscular depot.¹⁵⁹²

Detection time

In a one-volunteer study, selected urinary markers were detected up to 24 days with one extraction method and seven days with direct injection. The method and metabolite affect detection; these values cannot provide a personal clearance date.¹⁵⁹³

Direct and mixed-exposure safety findings

6 of 9

Six of nine hemodialysis patients developed marked reversible hypertriglyceridemia after one to three months of oral treatment. The publisher abstract omits the placebo-group size.¹⁵⁸³

Two powerlifter cases

A 2025 report describes anxiety, irritability or depression during mixed-steroid use. One man improved after stopping; the other continued and did not fully remit during three months of follow-up. Both had multiple steroids detected in urine.¹⁵⁹⁴

Spontaneous reports

The audit found 91 distinct FDA report IDs after version deduplication across exact-name queries. All listed other drugs. The database supplies no exposed-user denominator for a drostanolone risk estimate.^1595,1596

Unexpected ingredients

An Australian sample study found unexpected drostanolone enanthate in two raw powders labeled testosterone enanthate. FDA also documents a qualitative steroid-identification method. Neither source rates the product market as a whole.^1597,1598

Current product and sport status

United States: discontinued

The 2026 Orange Book lists Drolban 50 mg/mL in its discontinued section. The current application dataset gives the same status. FDA review appendices cite withdrawal effective March 2,1994; the original notice and reason are unresolved.^{1580,1599,1600}

Federal controlled-substance classification

Current 21 CFR 1308.13 names drostanolone under Schedule III, code 4000. The governing anabolic-steroid language includes esters.^1601,1602

Tested sport

Drostanolone is named under S1.1 in the current 2026 WADA list, prohibited at all times. Ester language is included. The published 2027 list keeps that classification and takes effect January 1,2027.^1603,1604

Identity and esters

01 What is drostanolone?

Drostanolone, also called dromostanolone, is an anabolic androgenic steroid derived from dihydrotestosterone. Historical medicines used the propionate ester. Masteron, Masteril and Drolban appear in historical drug records.^{1578,1579,1605}

02 Are Masteron and drostanolone the same thing?

Masteron is a historical trade name associated with drostanolone propionate. The shared product name does not identify the ester, concentration or ingredients in a present-day product.^{1579,1605,1597}

03 What is the difference between propionate and enanthate?

They attach different ester groups to the same parent steroid and have distinct chemical records. Historical cancer studies generally used propionate. The cited evidence does not establish a controlled human enanthate benefit, safety profile or systemic half-life.^{1579,1581,1582,1593,1584}

04 Is drostanolone a peptide?

Drostanolone is a steroid. Its parent molecule has the formula C20H32O2; it is chemically different from a chain of amino acids.¹⁵⁷⁸

Human studies

01 Why was drostanolone used for breast cancer?

Doctors studied androgen treatment for advanced breast cancer before current treatment options existed. The historical drostanolone reports describe selected cancer populations and different comparators. The results apply to those historical populations and comparisons.^{1585,1587,1582}

02 What happened in the 20-woman cancer report?

The 1963 publisher abstract reports six objective improvements, nine unchanged cases and five cases of progression among 20 women with advanced breast cancer. Improvement lasted an average of 5.8 months, with a maximum of eight months. The complete article body was unavailable in the accessible sources.¹⁵⁸⁵

03 Who wrote the 1963 breast-cancer paper?

Sergio Di Pietro and Bruno Salvadori. PMID 14027591 identifies their 1963 paper; its English and Italian abstracts give different treatment schedules.¹⁵⁸⁵

04 What did the 91-patient controlled study find?

The study compared drostanolone, nandrolone and testololactone and found no efficacy difference among the groups. Cyclophosphamide was added later. The abstract's remission percentages pool treatment groups, so they cannot supply a drostanolone-only response rate.¹⁵⁸²

05 Did a larger dose work better in metastatic breast cancer?

A historical dose comparison reported regression in 22% with the lower propionate exposure and 16% with the higher exposure, with P=.325 and no reported survival difference. The publisher abstract omits arm sizes and treatment duration.¹⁵⁸⁶

06 Did Masteril outperform other cancer treatments?

The 1975 abstract reports different response directions across comparisons with oophorectomy, nandrolone and estrogen in different menopausal groups. It omits group denominators and allocation details. Those results do not establish one overall superiority claim.¹⁵⁸⁷

07 Was it studied for benign breast lumps?

Small Japanese studies examined mastopathy, a benign breast condition. A randomized dose study evaluated 38 participants and found no significant group differences in pain, tenderness or softening; lump reduction and weight gain varied with exposure.¹⁵⁸⁹

08 What doses and durations were used in the human studies?

Historical treatment differed by route and disease. The oral-parent kidney trial used 200-400 mg/day for one to three months. The 1963 cancer abstract reports 100 mg intramuscularly three times weekly for two weeks to eight months in English, while its Italian version says alternate days. These are descriptions of study exposure.^1583,1585

Appearance, muscle and stacks

01 Does Masteron reliably make someone look harder or drier?

The cited human studies do not quantify that cosmetic effect. The strongest direct clinical records concern historical breast conditions and an oral-parent study in kidney patients. A physique description has no validated effect size in this evidence set.^{1582,1583,1589,1584}

02 Does it cause fat loss?

No controlled human fat-loss result appears in the cited evidence. The historical cancer and breast-condition studies did not test a modern fat-loss program. Changes in body weight in those studies cannot be relabeled as measured fat loss.^{1589,1582,1584}

03 Is there a proven body-fat level where it starts working?

The cited clinical studies establish no body-fat threshold for a visible response.^{1582,1589,1584}

04 Does it have a proven muscle or strength benefit?

The studies appraised here provide no controlled drostanolone-specific estimate for muscle gain or strength in healthy users. Human laboratory studies can detect exposure but did not measure a training benefit.^1584,1606

05 What does the evidence say about stacks with testosterone or other steroids?

The cited evidence does not establish a controlled cosmetic benefit or safety rate for a drostanolone stack. Modern reports often involve several substances at once, so their findings belong to those combined exposures.^{1584,1606,1595}

Side effects and product testing

01 What did the kidney-patient study find?

In a 1974 controlled trial, six of nine hemodialysis patients receiving oral dromostanolone developed marked but reversible hypertriglyceridemia after one to three months. The abstract gives no placebo-group size. The investigators could not assess anemia benefit over the short treatment period.¹⁵⁸³

02 Is the oral study evidence about injectable Masteron?

The kidney-patient trial used oral parent drug in people receiving hemodialysis. Its lipid finding adds a direct human safety signal, but the route and population differ from intramuscular propionate and enanthate products.^{1583,1579,1581}

03 What does the evidence say about liver safety?

The short oral-parent kidney study reported no hepatotoxicity. A separate aplastic-anemia report pooled several androgen treatments and cannot give a drostanolone-specific liver-risk rate. Long-term safety requires more than these historical observations.^1583,1607

04 Was virilization reported in women?

Yes. The 1963 series reported one marked virilization event among 20 women. Japanese breast-condition studies also recorded androgen-related symptoms in small treatment groups. Those short historical reports cannot estimate modern long-term risk.^{1585,1589,1590}

05 Are there reliable rates for hair loss, acne or voice changes?

The available drostanolone reports are small, historical or involve multiple steroids. They record some androgenic symptoms but do not provide reliable rates for present-day cosmetic use. FDA also describes serious harms from steroid-containing bodybuilding products at the broader product-class level.^1589,1608

06 Does FDA's adverse-event database show reports?

Eight exact-name queries returned 136 overlapping record appearances. After retaining the highest returned version for each safetyreportid, the audit found 91 distinct report IDs; all listed other drugs and 86 carried serious flags. The database has no exposed-user denominator for calculating risk.^1595,1596

07 Can a label or a COA prove what is in a product?

A label is a claim about contents. A laboratory result needs a traceable sample, an appropriate method and a clear account of what was measured. An Australian sample study found unexpected drostanolone enanthate in two raw powders labeled testosterone enanthate. It does not provide a counterfeit rate for all drostanolone products.^1597,1598

08 Can it affect fertility or testosterone recovery?

A 2025 report of two men using several steroids found suppressed LH and FSH. The returned FDA reports also include infertility and testicular atrophy with other reported drugs. These records do not establish a drostanolone-specific fertility rate or a tested recovery/PCT schedule.^{1594,1595,1584}

09 Is a libido boost predictable?

The studies appraised here provide no controlled estimate for a drostanolone libido benefit. One man in a 2025 mixed-steroid case report had reduced libido that returned after the whole regimen stopped. That observation cannot predict an individual response.^1594,1584

10 What is known about mood and psychiatric effects?

A 2025 report describes two powerlifters with anxiety, irritability or depression during mixed-steroid use. One improved after stopping the regimen; the other continued use and did not fully remit during three months of follow-up. Both had multiple steroids detected in urine.¹⁵⁹⁴

Androgens and estrogen questions

01 How does drostanolone work?

Drug-reference records classify drostanolone propionate as an androgen-receptor agonist. That mechanism explains its androgenic activity; clinical outcomes still depend on the population, formulation and study.^1605,1582

02 Can it replace an aromatase inhibitor?

Historical drostanolone activity in breast cancer is not a validated replacement for an aromatase inhibitor or an estrogen-control protocol for people using other hormones.^{1587,1582,1605,1584}

03 Does it prevent gynecomastia?

No controlled gynecomastia-prevention outcome was identified in the reviewed drostanolone studies. The historical breast-treatment papers cannot answer whether it prevents breast enlargement during another steroid exposure.^{1589,1587,1584}

Half-life, detection and onset

01 Is its half-life 5.3 hours?

That number comes from a three-volunteer Korean urine study. Its Methods identify an oral propionate exposure; the paper reports a 5.31-hour half-life for unchanged-drug urinary excretion. It did not measure an intramuscular depot or plasma half-life.¹⁵⁹²

02 What does the three-percent urine result mean?

The Korean study recovered about 3% of the administered amount as unchanged drug in urine through 95 hours. The table's 87.9% value, labeled 24 hours, is a share of that recovered unchanged urinary drug. Collection times differ between Methods and Table 1.¹⁵⁹²

03 Why can a doping test stay positive after the drug level falls?

Tests can look for metabolites as well as parent drug, and detection depends on the method and sample. In a one-volunteer analytical study, selected urinary markers were detected up to 24 days with one extraction method and seven days with direct injection. Those windows do not measure treatment duration or establish a personal clearance date.¹⁵⁹³

04 Is there a validated enanthate half-life or injection interval?

No controlled human systemic pharmacokinetic record for enanthate appears in the cited evidence. Chemical-reference records and urinary marker studies cannot establish an injection interval.^{1581,1593,1584}

05 How soon should visible effects appear?

The cited evidence establishes no reliable time to a harder appearance, fat loss or muscle gain in healthy users. Historical cancer response measures treatment effect; urinary detection measures analyte persistence.^{1584,1585,1593}

Availability, regulation and sport

01 Is Drolban currently available as an FDA-listed medicine?

FDA's current application record and the 2026 Orange Book place Drolban in discontinued status. Historical FDA review appendices cite withdrawal effective March 2,1994. The original withdrawal notice and its reason were not located.^{1599,1580,1600}

02 Does an FDA substance number mean the drug is approved?

No. A UNII identifies a substance. FDA's substance-record page explicitly says the availability of a UNII does not imply regulatory review or approval. Application and product records document approval and marketing status.^{1609,1610,1599}

03 How is drostanolone controlled in the United States?

Current federal regulations name drostanolone under Schedule III, drug code 4000. The governing anabolic-steroid language covers esters as well as the parent substance. This is a controlled-substance classification.^1601,1602

04 Is it prohibited in tested sport?

Yes. The current 2026 WADA list names drostanolone under S1.1, prohibited at all times, and the class language includes esters. The published 2027 list keeps that classification and takes effect January 1,2027.^1603,1604

05 Are there modern registered clinical trials?

The completed ClinicalTrials.gov and five exact-name CTIS searches found no eligible drostanolone trial identity. Some other registry routes were inaccessible or returned search shells, and additional long chemical aliases remain unchecked. This is a bounded search result.^1611,1612